Analyses of Interleukin-6, Presepsin and Pentraxin-3 in the Diagnosis and Severity of Late-onset Preeclampsia

This observational case-control study was designed at Cengiz Gokcek Women's and Children's Hospital, Gaziantep, Turkey, in the Department of Obstetrics and Gynecology between June 2018 and January 2019. The protocol was approved by the Ethics Committee for Clinical Research of Gaziantep University (Reference number: 2018/393). The study strictly adhered to the principles of the Declaration of Helsinki. All subjects included in the study gave oral and written informed consent. Eighty-eight women were enrolled in the study in two groups. All participants will gave their oral and written informed consent before their inclusion in the study.

Inclusion criteria

• preeclampsia healthy pregnancy

Exclusion criteria

• pregnant women with any systemic condition (such as chronic hypertension, inflammatory and rheumatic diseases),
• using any kind of medication throughout pregnancy (such as acetylsalicylic acid, corticosteroids or heparin),
• pregnant women who had fever at the time of the first admission,
• concurrent infections (urinary tract infection, cervicitis, etc.),
• pregnancies complicated with premature membrane rupture or chorioamnionitis,
• history of medication for PE treatment at the time of the first admission,
• patients who had fetal congenital abnormalities or genetic syndromes,
• drug user,
• multiple gestations,
• active labor.